Journal article
A pharmacoeconomic evaluation of two new products for the treatment of overactive bladder.
Abstract
The objective of this study is to evaluate the cost effectiveness of two new treatments for overactive bladder: once-daily controlled-release oxybutynin, and twice-daily tolterodine, with a comparison with oxybutynin immediate release. Also estimated are the potential cost savings to a health plan budget resulting from increased utilization of the most cost-effective treatment. The design is a decision-tree model based on clinical trial data …
Authors
Arikian SR; Casciano J; Doyle JJ; Tarride JE; Casciano RN
Journal
Managed Care Interface, Vol. 13, No. 2, pp. 88–94
Publication Date
2 2000
ISSN
1096-5645